Predicting CRS using humanized mice

November 20, 2020

Alba Matas Céspedes, Astra Zeneca Title: Use of human splenocytes in an innovative humanized mouse model for prediction of immunotherapy-inducedcytokine release syndrome

Predicting CRS using humanized mice

Leveraging Gene Therapy to Achieve Long-Term Continuous or Controllable Expression of Biotherapeutics

Mesothelin-specific CAR-T Cell Therapy with HLA-gated Safety Mechanism Selectively Kills Tumor Cells

CAR T-cell Cytotoxicity of Solid Tumors is Dependent on IFNγR Signaling & Downstream Adhesion

DROSHA but not DICER is Required for Human Haematopoietic Stem Cell Function

Novel Humanized Mouse Model for Assessment of Human Allogeneic Responses in Organ Transplantation

Modeling Human Melanoma To Understand And Treat Resistance To Immunotherapy

Immune-Humanized PDX Model-Estrogen-Independent, Hormone Receptor-Positive Metastatic Breast Cancer

A Novel Clinically Relevant Graft-Versus-Leukemia Model in Humanized Mice

T Cells Targeted to TdT Kill Leukemic Lymphoblasts While Sparing Normal Lymphocytes

NOD/scid IL-2Rγnull Mice Reconstituted with Peripheral Blood Mononuclear Cells of Crohn’s Disease

Src/lck Inhibitor Dasatinib Reversibly Switches Off Cytokine Release and T Cell Cytotoxicity

HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2

Robust CAR-T Memory Formation and Function via Hematopoietic Stem Cell Delivery

Human KIT+ Myeloid Cells Facilitate Visceral Metastasis By Melanoma

Modeling Chimeric Antigen Receptor (CARS) and T Cell Bispecific (TCB) Therapies in Mice

Combining T-cell-specific activation & in vivo gene delivery through CD3-targeted lentiviral vectors

HuMouse models for the influence of genetic variation on the immune control of Epstein Barr

The application of humanized mouse models to study LILRB-mediated regulation of myeloid cells

Mode of Action of TCell Bispecific Antibodies and their Combinations with Checkpoint Inhibitors

PD1 Blockade Aggravates Epstein-Barr Virus+